Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Accumulated Expenses (2016 - 2026)

Achieve Life Sciences (ACHV) has disclosed Accumulated Expenses for 15 consecutive years, with $2.2 million as the latest value for Q1 2026.

  • Quarterly Accumulated Expenses rose 126.35% to $2.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Mar 2026, up 126.35% year-over-year, with the annual reading at $1.9 million for FY2025, 36.54% down from the prior year.
  • Accumulated Expenses for Q1 2026 was $2.2 million at Achieve Life Sciences, up from $1.9 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $3.0 million in Q4 2024, with the low at $663000.0 in Q1 2022.
  • Average Accumulated Expenses over 5 years is $1.6 million, with a median of $1.6 million recorded in 2025.
  • The sharpest move saw Accumulated Expenses tumbled 36.54% in 2025, then soared 126.35% in 2026.
  • Achieve Life Sciences' Accumulated Expenses stood at $1.7 million in 2022, then skyrocketed by 37.72% to $2.3 million in 2023, then skyrocketed by 30.98% to $3.0 million in 2024, then crashed by 36.54% to $1.9 million in 2025, then rose by 13.59% to $2.2 million in 2026.
  • Per Business Quant, the three most recent readings for ACHV's Accumulated Expenses are $2.2 million (Q1 2026), $1.9 million (Q4 2025), and $2.4 million (Q3 2025).